Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954265 | 0.84 | LMNA (0.42) | ESRRGLMNAKMT2AHDAC1HDAC7 | |
| SCHEMBL16096308 | 0.82 | ALDH1A1 (0.43) | LMNALOXL2MEN1KMT2AHDAC1 | |
| SCHEMBL3983398 | 0.81 | L3MBTL1 (0.49) | ESRRGMEN1KMT2AHPGDTMEM97 | |
| SCHEMBL29954315 | 0.81 | MAP2K1 (0.43) | HDAC1 | |
| SCHEMBL13644472 | 0.79 | MAOB (0.41) | ESRRGLMNAMEN1KMT2ATMEM97 | |
| SCHEMBL3682591 | 0.79 | LMNA (0.51) | LMNAKMT2ACNR2HPGD | |
| SCHEMBL14743123 | 0.79 | MAP2K2 (0.47) | ESRRGMEN1KMT2AHPGDTMEM97 | |
| SCHEMBL29125458 | 0.79 | TSHR (0.40) | LMNAMAPK1KMT2AHDAC1HDAC7 | |
| SCHEMBL15798271 | 0.79 | HDAC6 (0.46) | LMNAHDAC6HDAC1 | |
| SCHEMBL29955902 | 0.79 | HTT (0.53) | LMNAHDAC1HPGDTMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9217000-B2 | Targeted nitroxide agents | Univerisyt of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140018317-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20120207687-A1 | TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207687-A1 | TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTS | NOX1, OGG1, NOX5 | ESRRG 1243/4885BRAF 2376/4885LMNA 2306/4885 |
| US-20140018317-A1 | TARGETED NITROXIDE AGENTS | NOXO1, NOX1, TPX2 | ESRRG 188/4885BRAF 876/4885LMNA 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.